|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
Dec 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
Jul 2020 |
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
Jan 2024 |
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
Jun 2023 |
Molecular Medicine |
Aplastic Anemia |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Mar 2019 |
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
